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Abstract
Background
The control of schistosomiasis emphasizes preventive chemotherapy with praziquantel,
which aims at decreasing infection intensity and thus morbidity in individuals, as well as
transmission in communities. Standardizing methods to assess treatment efficacy is impor-
tant to compare trial outcomes across settings, and to monitor program effectiveness con-
sistently. We compared customary methods and looked at possible complementary
approaches in order to derive suggestions for standardizing outcome measures.
Methodology/Principal Findings
We analyzed data from 24 studies conducted at African, Asian, and Latin American sites,
enrolling overall 4,740 individuals infected with Schistosoma mansoni, S. haematobium, or
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S. japonicum, and treated with praziquantel at doses of 40–80 mg/kg. We found that group-
based arithmetic and geometric means can be used interchangeably to express egg reduc-
tion rates (ERR) only if treatment efficacy is high (>95%). For lower levels of efficacy, ERR
estimates are higher with geometric than arithmetic means. Using the distribution of individ-
ual responses in egg excretion, 6.3%, 1.7% and 4.3% of the subjects treated for S. haema-
tobium, S. japonicum and S.mansoni infection, respectively, had no reduction in their egg
counts (ERR = 0). The 5th, 10th, and 25th centiles of the subjects treated for S. haematobium
had individual ERRs of 0%, 49.3%, and 96.5%; the corresponding values for S. japonicum
were 75%, 99%, and 99%; and for S.mansoni 18.2%, 65.3%, and 99.8%. Using a single
rather than quadruplicate Kato-Katz thick smear excluded 19% of S.mansoni-infected
individuals. Whilst the effect on estimating ERR was negligible by individual studies, ERR
estimates by arithmetic means were 8% lower with a single measurement.
Conclusions/Significance
Arithmetic mean calculations of Schistosoma ERR are more sensitive and therefore more
appropriate to monitor drug performance than geometric means. However, neither are satis-
factory to identify poor responders. Group-based response estimated by arithmetic mean
and the distribution of individual ERRs are correlated, but the latter appears to be more
apt to detect the presence and to quantitate the magnitude of suboptimal responses to
praziquantel.
Author Summary
To identify whether a person is infected with parasitic worms, stool or urine samples are
examined for worm eggs. The drug praziquantel is used against the parasitic disease schis-
tosomiasis. However, there is no definitive agreement as to how the efficacy of praziquan-
tel is best expressed. We put together a database from various studies of the efficacy of
praziquantel against schistosomiasis. Efficacy was measured using customary methods:
cure rate (CR: percentage of people with eggs in their stool/urine before treatment who
became egg-negative after treatment); and egg reduction rate (ERR; percentage reduction
in the number of eggs in the stool/urine after treatment, where the mean number of eggs
from all people treated is calculated using either geometric or arithmetic means). We
found that arithmetic and geometric means can be used interchangeably only if treatment
efficacy is very high; arithmetic means are more sensitive to capture drops in efficacy
expressed by ERR. A valid complement for drug efficacy monitoring is to study the distri-
bution of individual responses in egg excretion that allows identifying in a single measure
both those who had an adequate response to treatment and those who respond less well;
e.g., the 5% of the patients with the lowest ERRs.
Introduction
Schistosomiasis is a parasitic disease caused by blood flukes of the genus Schistosoma. The
three main species infecting humans are S. haematobium (causing urogenital schistosomiasis),
S. japonicum, and S.mansoni (the latter two responsible for intestinal schistosomiasis) [1]. The
backbone of the global strategy for controlling the morbidity caused by schistosomiasis is the
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periodic administration of single-dose oral praziquantel (usually given at 40 mg/kg body
weight). This strategy is termed “preventive chemotherapy”, whereby praziquantel is adminis-
tered without prior diagnosis [2,3] to entire communities or target groups, most
importantly school-aged children [4–6], depending on the level of endemicity [7,8].
How efficacy of antischistosomal drugs (and anthelmintic treatments in general) should be
measured has been, and still is, a matter of debate in the research and disease control commu-
nities. One limitations of the current treatment outcome measure–i.e., parasite egg excretion–is
that it is a proxy for drug effects on adult worms, which could also be confounded by various
factors, including facultative temporary cessation of excretion by the adult worm [3]. Other,
more direct but not yet widely used methods of worm vitality are the detection of specific anti-
gens, like the circulating cathodic antigen (CCA) and the circulating anodic antigen (CAA)
[9,10]. Clinical trials have traditionally used cure rates (CRs) as the main drug efficacy end-
point, and expressed results as the proportion of infected individuals who convert to a negative
stool or urine sample post-treatment [11–13]. However, the World Health Organization
(WHO) recently issued guidelines that recommend the egg reduction rate (ERR) as the pri-
mary outcome measure, especially when assessing programmatic treatment effectiveness [3].
This entails a quantitative diagnostic test based on the microscopic detection and enumeration
of parasite eggs in small amounts of stool (usually 41.7 mg) and the estimation of the number
of eggs per 1 g (EPG) of feces (S. japonicum or S.mansoni) or per 10 ml of urine (S. haemato-
bium). The ERR measures the overall effect of treatment on the entire group of infected sub-
jects treated (ignoring individual variability) and is expressed as the ratio between the mean of
the pre- and post-treatment egg counts [3]. ERR is considered more suitable than CR to assess
the impact of preventive chemotherapy on morbidity (which is commensurate to infection
intensity) in the context of continuous risk of reinfection and in view of the low sensitivity of
current diagnostic methods [12,14].
Which type of means (e.g., geometric mean (GM) or arithmetic mean (AM)) should be
used to express treatment outcomes against helminthiases at the community level is an addi-
tional subject of debate [15,16]. Thus far, studies of treatment efficacy have predominantly
reported results using GM egg counts [15] but recently, the use of AM egg counts has been
advocated [17,18]. The issue is that egg counts are not normally distributed, even after logarith-
mic transformation, which would call for using GM [19]. However, GM hide extreme values
(e.g., (i) a small proportion of individuals disproportionally contributing to total egg excretion,
and (ii) individuals who do not respond to treatment), which are important when assessing the
effects of interventions, and which are better captured by using AM.
A further complication when dealing with different studies is the diversity in methodologies,
in particular: (i) which diagnostic method is used (e.g., single or multiple urine filtration for
detection of S. haematobium eggs) [20] or the Kato-Katz technique for detection of S. japoni-
cum or S.mansoni eggs in fecal samples, whose sensitivity depends upon the baseline infection
intensity, the number of thick smears from a single sample, and the number of stool specimens
examined [21–24]; and (ii) how many weeks post-treatment effects are measured, which also
depends on Schistosoma species [25,26].
The objectives of this paper were to compare customary methods to assess the efficacy of
praziquantel for treating schistosomiasis and to explain differences; to identify possible alterna-
tive approaches to express treatment effects on egg excretion; and to verify whether the size of
treatment effects for intestinal schistosomiasis change when measured with a single or
quadruplicate Kato-Katz thick smears. The overall aim of these analyses was to derive sugges-
tions for standardizing outcome measures in future drug efficacy studies. For this purpose, we
combined and analyzed available data from various studies where praziquantel was used to
treat infections with different Schistosoma species.
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Methods
Ethics Statement
All studies selected for the current secondary analyses had been approved by the relevant insti-
tutional review boards and ethics committees, and were conducted according to international
ethics standards (for details, see individual publications [25–36]). Data received from the indi-
vidual studies were completely anonymized.
Datasets Analyzed
We built a common database from 24 studies including 4,740 individuals assigned to three dif-
ferent treatment groups who had received either 40 mg/kg (18 studies, 3,713 individuals), 60
mg/kg (five studies, 690 individuals), or 80 mg/kg (one study, 337 individuals) praziquantel
against S. haematobium [25,27–29,34,36], S. japonicum [31,32], and S.mansoni [21,23,26–
28,30,31,33,35].
The main study characteristics, including Schistosoma species, praziquantel dose, age of
participants, time-point of treatment follow-up, and diagnostic approach, are summarized in
Table 1. Studies enrolled a total of 4,740 individuals, of whom 2,633 (55.5%) were infected with
S. haematobium, 1,804 (38.1%) with S.mansoni, and the remaining 303 (6.4%) with S. japoni-
cum. Studies generally enrolled children and adolescents except one study in the People’s
Republic of China [32] and another one in Côte d’Ivoire [33]. The praziquantel dose was 40
mg/kg in 17 studies, 60 mg/kg in five studies, and 80 mg/kg in one study. Follow-up was within
3 weeks in 13 studies, four weeks in two studies, within 2 months in six studies, and longer in
the remaining three studies.
For the detection of S. haematobium infection, two diagnostic approaches were employed:
(i) a single urine filtration slide in five studies (one of them was carried out on the same sample
but at two different time points) [25,26,28,29,34]; and (ii) duplicate urine filtration slides in
one study [36]. For the diagnosis of S. japonicum, duplicate Kato-Katz thick smears from each
of two stool specimens were subjected to microscopic examination in all studies. For the detec-
tion of S.mansoni, the most common diagnostic approach was duplicate Kato-Katz thick
smears from each of two stool specimens. In one study, a single Kato-Katz thick smear was per-
formed on five samples at baseline and triplicate Kato-Katz thick smears for four samples
at follow-up [35,37].
Efficacy Outcomes and Calculations
Treatment response was assessed both at the overall group and the individual level. The AM
and GM EPG values were calculated at pre- and post-treatment for S. mansoni and S. japoni-
cum by multiplying the individual fecal egg counts (FECs) obtained by a single Kato-Katz thick
smear (41.7 mg) by a factor of 24. For S. haematobium, egg counts are presented as eggs per
10 ml of urine. Drug efficacy was expressed as ERR and CR.
ERR (arithmetic (ERRAM) or geometric (ERRGM)) was calculated as the ratio of the difference
between the (arithmetic or geometric) means of the pre- and post-treatment EPG or eggs per 10 ml
urine to the pre-treatment (arithmetic or geometric) mean EPG or eggs per 10 ml urine: ERR =
[(mean egg countpre-treatment −mean egg countpost-treatment) / mean egg countpre-treatment] x 100
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GM egg counts were calculated as follows: exp
Xi¼njk
i¼1
lnðxijk þ cÞ
njk
2
66664
3
77775
 c, where xijk is the
observed egg count for individual host i, Schistosoma species j, and study k; njk is the number of
hosts who provided a (pre- and post-treatment) sample for determination of infection intensity
for each Schistosoma species and study, and c is a constant added to each count to allow inclu-
sion of zero counts (negative test) [38]. Confidence intervals (CIs) for the ERR (calculated
with AM and GM) were determined by using a bootstrap resampling method (with replace-
ment) over 1,000 replicates and expressed as a univariate calculation of the 2.5th and 97.5th
percentiles.
Table 1. Study and individuals’ main characteristics.
Study, year
[reference]
Species1 Praziquantel dose
(mg/kg)
Age2 Follow-up
(days)
Diagnostic approach at pre- and post-treatment
Côte d’Ivoire, 2011
[28]
Sh 40 3.7 ± 1.1 21 Single filtration per urine sample
Niger, 2007 [27] Sh 40 9.1 ± 2.2 42 Three consecutive urine samples over three days, filtered once
Niger, 2009 [27] Sh 40 10.1 ± 2.3 21 Three consecutive urine samples over three days, filtered once
Côte d’Ivoire, 2000
[34]
Sh 80 9.5 ± 2.6 52 Single filtration per urine sample
Mali, 2006 [29] Sh 40 10.4 ± 2.3 182.5 Single filtration per urine sample
Mali, 2009 [29] Sh 40 3.6 ± 1.2 365 Single filtration per urine sample
Côte d’Ivoire, 2010
[25]
Sh 40 11.0 ± 2.2 21 Single filtration per urine
Kenya, 1990 [36] Sh 40 11.2 ± 3.3 45 Duplicate filtration per urine sample × 2 samples
Philippines, 2007 [31] Sj 40 12.5 ± 2.0 21 Duplicate KK per stool sample × 2 samples
Philippines, 2007 [31] Sj 60 12.4 ± 2.0 21 Duplicate KK per stool sample × 2 samples
People’s Republic of
China, 2007 [32]
Sj 40 46.1 ± 14.5 90 Triplicate KK per stool sample × 3 samples
Côte d’Ivoire, 2011
[28]
Sm 40 3.8 ± 1.2 21 Duplicate KK per stool sample × 2 samples
Uganda, 2012 [30] Sm 40 4.1 ± 1.7 42 Duplicate KK per stool sample × 2 samples
Brazil, 2007 [31] Sm 40 15.2 ± 2.8 21 Duplicate KK per stool sample × 2 samples
Brazil, 2007 [31] Sm 60 14.9 ± 2.5 21 Duplicate KK per stool sample × 2 samples
Mauritania, 2007 [31] Sm 40 12.6 ± 2.0 21 Duplicate KK per stool sample × 2 samples
Mauritania, 2007 [31] Sm 60 12.6 ± 2.1 21 Duplicate KK per stool sample × 2 samples
Tanzania, 2007 [31] Sm 40 12.3 ± 1.8 21 Duplicate KK per stool sample × 2 samples
Tanzania, 2007 [31] Sm 60 12.7 ± 2.1 21 Duplicate KK per stool sample × 2 samples
Côte d’Ivoire, 2004
[33]
Sm 40 21 ± 49.4 42 Single KK per stool sample × 3 samples
Côte d’Ivoire, 2007
[26]
Sm 40 8.9 (5–13)* 20 Duplicate KK per stool sample × 2 samples
Côte d’Ivoire, 1997
[35]
Sm 40 9.3 (6–14)* 28 Single KK per stool sample × 4 samples
Côte d’Ivoire, 1998
[35]
Sm 60 10 (7–14)
**
28 Five consecutive stool samples (1 KK per sample) at pre-
treatment and four consecutive stool samples (3 KK per
samples) at post- treatment
1Species: Sh = Schistosoma haematobium, Sj = Schistosoma japonicum, Sm = Schistosoma mansoni.
2Age is expressed as the mean ± standard deviation, except for *mean (range) and ** median (range).
doi:10.1371/journal.pntd.0003821.t001
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Individual ERR was calculated as the ratio of the difference between the pre- and post-
treatment EPG or eggs per 10 ml urine to the pre-treatment EPG or eggs per 10 ml urine multi-
plied by 100.
CRs and 95% binomial CIs were the percentage of infected individuals negative for Schisto-
soma (in their urine or stool) at post-treatment follow-up. The distribution of individual
responses in egg excretion was categorized as (i) negative (corresponding to CR), (ii) reduction,
(iii) no change or increase, and further expressed in centiles to quantitate the fraction of poor
responders.
Comparing Methods of Assessing Drug Efficacy
We compared (i) the ERRAM versus ERRGM and (ii) the CR versus ERR. The results were pre-
sented graphically in modified L’Abbé plots with 95% CIs for both comparisons, and addition-
ally in Bland and Altman plots for ERR using AM and GM. The coefficient of determination
(R2) was also calculated.
A linear mixed model of the difference of the ERRs calculated as GM and AM (ΔERRg,a)
was developed to estimate which parameter could better predict the difference between the two
ERR calculations, with the average of the two mean ERRs (GM and AM) set as covariate. Such
a model was extrapolated from the Bland and Altman regression by further including predic-
tive factors. In order to evaluate the effect of different factors on ΔERRg,a, the ERR was calcu-
lated on the different strata defined by the combination of the categories of the following
parameters: age, sex, treatment dose, and Schistosoma species. The same age categories were
defined across all studies. The linear mixed model was estimated including these parameters as
independent factors. 95%CIs of the difference between the two ERR calculations were calcu-
lated by using Tango’s score confidence interval which was shown in the literature to outper-
form other calculation methods in the case of correlated proportions [39,40].
Modeling was carried out through a shrinkage method of variable selection. Variables were
first selected using the ElasticNet procedure, which is mixing a least absolute shrinkage and
selection operator (LASSO) procedure and ridge regression [41]. Subsequently, a variance-
covariance matrix structure was selected among unstructured, variance components, autore-
gressive, compound symmetry and Toeplitz structures, which minimized the Aikake informa-
tion criterion corrected (AICC) for finite sample size. Post-hoc tests on each parameter were
carried out with a Tukey adjustment. Pairwise differences in least square means (LSM) were
calculated for fixed values of the average of the AM and GM ERRs (for the range 70–99%),
thereby evaluating the influence of exogenous parameters on the bias between the two ERRs.
This bias was evaluated in the Bland and Altman method by regressing the difference of the
two methods by their mean.
All tests were two-tailed; a p-value of 5% was deemed significant. Only studies with
treatment follow-up examination done within 90 days were included in the models (to mini-
mize the effect of reinfection after praziquantel administration). Calculations and analyses
were performed by using SAS system version 9.3 (SAS Institute, Cary, NC, United States of
America).
Comparing Efficacy Assessments Based on Single versus
Quadruplicate Kato-Katz Thick Smears for S. mansoni
For S. mansoni, we compared single (using the first thick smear on the first stool specimen)
versus quadruplicate (using four thick smears of the same stool specimen) Kato-Katz thick
smears for expressing CR and ERR (with AM and GM). In this sub-analysis, we only included
individuals infected with S. mansoni whose first slide on the first fecal sample was positive.
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Within this population, we calculated and compared the overall AM and GM pre- and post-
treatment FECs and the respective ERRs and CRs based on single and quadruplicate Kato-
Katz thick smears with 95% CIs calculated by boot-strapping. The results of the individual
studies were presented graphically in Bland and Altman plots and in modified L’Abbé plots
with 95% CIs, and the coefficient of determination (R2) was calculated.
Results
Study Characteristics
The distributions of the raw egg counts at baseline by Schistosoma species for each study
(including AMs and GMs) are presented in Fig 1. Efficacy outcomes were analyzed on a total
of 4,375 individuals with pre- and post-treatment egg counts. Among them, 2,365 (54.1%)
were infected with S. haematobium, 1,708 (39.0%) with S.mansoni, and the remaining 300
(6.9%) with S. japonicum. Details of baseline FECs and drug efficacy outcomes, including
group-based means and individual responses by study and Schistosoma species, are presented
in Table 2.
Comparing ERRs Obtained with AM versus GM
ERRAM ranged from 17.0% to 99.8% and ERRGM from 50.7% to 99.8% for S. haematobium;
81.5–100% (ERRAM) and 95.9–100% (ERRGM) for S. mansoni; 83.5–99.9% (ERRAM) and 86.9–
99.9% (ERRGM) for S. japonicum. The 95% CIs estimated by boot-strapping tended to be wider
with AM compared to GM. Among the 24 studies included in our analyses, six had an ERR
<90% by AM (two if restricted to studies with 3 weeks’ follow-up), but only two by GM.
The modified L’Abbé plot (Fig 2A) indicates that ERRs tend to be higher when calculated
using GM. The R2 of the linear regression showed a strong linear correlation for S. japonicum
(R2 = 1.00, three studies) and S. haematobium (R2 = 0.88, eight studies), but a weaker linear
correlation for S.mansoni (R2 = 0.46, 13 studies).
Modeling Group-Based ERRs
The mixed linear model found a significant relationship between the difference between
ERRAM and ERRGM and their mean value. However, introducing the variables identified as pre-
dictors by the ElasticNet procedure, coupled with model averaging based on 1000 replicates
(sampling with replacement)–mean baseline epg, year of study and species–rendered this
relation non-significant (meaning that none of these covariates could explain the differences
between ERRAM and ERRGM.)
LSM pairwise comparisons and ERR (individually for AM and GM) models showed a sig-
nificantly better consistency between ERRs calculated with AM and GM for S. haematobium
than for S.mansoni. Study participants’ age was found to have an effect only for ERRGM
(higher for school-aged children and adults than for preschool-aged children; S1 Table).
Distribution of Individual Treatment Responses in Egg Excretion
Group means and individual responses are presented in Table 2. Individual responses are also
displayed graphically in Fig 3 (panel A as bar diagrams; panel B as centile distributions). Over-
all, 6.3% (ranging in individual studies from 0 to 39%), 1.7% (0–5%); and 4.3% (0–11%) of the
subjects treated for S. haematobium, S. japonicum, and S.mansoni infection, respectively, had
no reduction in their egg counts (ERR = 0). The 5th, 10th, and 25th centiles of the subjects
treated for S. haematobium had individual ERRs of 0% (ranging in individual studies from 0 to
99.7%), 49.3% (0–100%), and 96.5% (0–100%); the corresponding values for S. japonicum were
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75.0% (0–97.4%), 99.0% (25.6–98.8%), and 99.0% (96.8–99%), and for S.mansoni 18.2% (0–
97.4%), 65.3% (0–99.4%), and 99.8% (0–99.8%).
The centile distribution of iERRs in studies with ERRAM<90% was shifted to the right and
clearly distinct from those with ERRAM90% (Fig 4).
When considering only studies assessing outcomes within a maximum of 28 days (13 stud-
ies evaluated drug efficacy at 21 days, two at 28 days), only two (both treating S.mansoni with
40 mg/kg praziquantel with 21-day follow-up [27,30]) had an ERRAM<90%; in terms of indi-
vidual responses, the 30th and 36th centile, respectively had ERRs<90%, and 10.8% and 7.1%
of patients, respectively had no change in their egg counts (ERR = 0). Three additional studies,
all with ERR AM>90%, had individual ERRs<90% in the 13th centile: one study on S.
Fig 1. Distribution of raw egg count at baseline by Schistosoma species and study. A. Schistosoma haematobium. B. Schistosomamansoni. C.
Schistosoma japonicum.
doi:10.1371/journal.pntd.0003821.g001
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haematobium treated with 40 mg/kg and 21-day follow-up [27], and two studies on S.mansoni
treated with 40 or 60 mg/kg with 28-day follow-up [35,37]. In these studies, 3.2%, 3.5% and
2.4%, respectively of individuals had no decrease in egg counts. Across these studies, ERRAM
and iERR were highly correlated (R2 0.95).
Comparing CR versus ERR
For all three Schistosoma species, the CR was systematically lower than ERR, regardless of
whether AM or GM was employed, except in a single study [29]. ERR>90% corresponded to
CRs ranging from 51.4% to 99%. Only when ERRs were very high (range: 97.7–100%) there
was a good agreement between both indicators. The CR ranged from 82.1% to 100% (Fig 5).
Multiple versus Single Kato-Katz Thick Smear Examination for S.
mansoni
Among the 1,435 individuals enrolled in the studies who were found positive for S. mansoni
eggs in their stool based on quadruplicate Kato-Katz thick smears, 1,167 (81.3%) were diag-
nosed positive on the first Kato-Katz thick smear. In this subset, we found that the results in
the individual studies were highly correlated (Fig 6A–6B; R2 = 0.95 for AM and R2 = 0.86 for
GM). The same number of studies (n = 2) had AM ERR of less than 90% with either approach.
On aggregate, the FECs at baseline were lower with quadruplicate than with a single Kato-
Katz thick smear when using either AM (1,046 EPG versus 2,617 EPG) or GM (342 EPG versus
575 EPG); the ERR estimates were comparable only by GM (99.5% versus 99.8%) whereas by
Fig 2. Comparison of egg reduction rate calculated as arithmetic mean (ERRAM) versus geometric mean (ERRGM), both with estimated 95%
confidence intervals (CIs). A. L’Abbé plot, B. Bland & Altman plot. For each point, the 95% CIs are shown in the L’Abbé plot, where the red dashed diagonal
line of no difference between the ERR calculated with both metrics. The blue dashed line represents the threshold for acceptable efficacy defined byWHO
[3].
doi:10.1371/journal.pntd.0003821.g002
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AM, the estimate was lower with quadruplicate than single examinations (86.9% versus 94.9%)
(Table 3). In order to verify if using a single Kato-Katz thick smear selected for a different sam-
ple, we compared the baseline FECs and ERRs assessed with quadruplicate Kato-Katz thick
smears on the overall sample of these studies (n = 1,435) to that of this subgroup with the
first Kato-Katz thick smear positive (n = 1,167): while the overall average baseline FECs was
approximately threefold lower for the latter, there was no difference in ERR between the two
groups for either AM and GM.
In contrast to ERRs, CRs derived from single versus quadruplicate Kato-Katz thick smears
were poorly correlated (R2 = 0.50) (Fig 7). With few exceptions, the CR assessed from single
Kato-Katz thick smear (CR = 92.0%) was consistently higher than that from quadruplicate
Kato-Katz thick smears (CR = 82.6%) in the individual studies and the difference between the
two approaches increased with decreasing efficacy (Fig 7A and 7B). The overall CR was 88.0%
applying a single and 79.0% using quadruplicate Kato-Katz thick smears (Table 4).
Fig 3. Distribution of individual ERR. A. Bar diagrams, B. Centile distribution.
doi:10.1371/journal.pntd.0003821.g003
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Discussion
Preventive chemotherapy with praziquantel is the current backbone of the global strategy to
control the morbidity caused by schistosomiasis in high-endemicity areas [2,4,6,8]. Monitoring
of praziquantel efficacy should accompany schistosomiasis control programs in order to iden-
tify promptly suboptimal responders; to that effect, the WHO has issued standard procedures
for control programs based on one single measurement around 3 weeks post-treatment [3]. At
the same time, more work is needed to improve the current evidence-base for decision-making:
in order to provide reliable information, it is important to agree on a robust statistical approach
to assess drug efficacy, especially in clinical trials, and to use standardized, quality-controlled
diagnostic methods that are comparable from one setting to another [18,42]. To date, both CR
and ERR (the latter based on either AM or GM), are used for assessing drug efficacy. The stool
and urine sampling and diagnostic approaches vary across studies, and these issues have
important ramifications for drug efficacy estimates.
Fig 4. Centile distribution of individual ERRs by species for all studies (A) and for studies with assessment within 28 days divided by ERRAM90%
and <90% (B).
doi:10.1371/journal.pntd.0003821.g004
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The controversy over the use of AMs or GMs to measure anthelmintic treatment efficacy as
assessed by ERR in parasitic nematodes of cattle, and more recently in those of humans, has
already been expounded in several studies, with contrasting results [43] favoring either AMs
[17], or GMs (see e.g. [15]) or pointing to inadequacies of both [44]. The overall aim of this
study was to compare and contrast different approaches to express treatment effects on Schisto-
soma infections in order to derive indications for standardizing future studies of drug efficacy.
The first specific objective of this paper was to compare customary measures of drug effi-
cacy. We first considered whether efficacy assessment based on ERR changes when using AM
or GM egg counts for the three predominant human Schistosoma species. While both means
were in the same range for all species and showed a moderate level of correlation, the discrep-
ancy between AM and GM became wider with decreasing drug efficacy. As previously reported
Fig 5. Comparison between egg reduction rate (ERR) and cure rate (CR). The red dashed diagonal line of no difference between the ERR calculated with
both metrics.
doi:10.1371/journal.pntd.0003821.g005
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by some [17,43,45]] but not all authors[17], GM estimates tended to be higher than AM. These
findings suggest that the two means can be used interchangeably if drug efficacy is high (ERR
>95%), but the difference between the two means is expected to increase as efficacy decreases.
It is also worth noting that two out of the 13 studies with assessment of efficacy within 3 weeks
would not meet the WHO threshold for acceptable efficacy of 90% [3] for ERR when calculated
by AM, while only 8% would not meet the WHO threshold, if calculated by GM (2/24). There-
fore, between the two, using AM, as suggested by WHO, appears to be more sensitive an
approach to identify problems with the response to praziquantel.
We employed models to help further qualifying these findings using explanatory variables.
We found that ERRs are more consistent between the AM and GM egg count values of S. hae-
matobium and S. japonicum than of S.mansoni infection, and for school-aged children and
adults than for preschool-aged children (but only when using GM). On the contrary, these
findings are not accounted for by the baseline and post-treatment distributions of the raw egg
counts (S2 Table), intensities of infection (S3 Table), or proportion of individuals with extreme
values (S2 Table). Together, these findings are important to allow a meaningful comparison of
newer studies using AM to older studies which would have used GM.
We then compared drug efficacy estimates by ERR (using AM or GM) versus CR. While
generally used in the past, the CR is known to have some major limitations, and is no longer
recommended by WHO for assessing the programmatic efficacy of drugs used in mass drug
administration [12,43,45]. As expected, efficacy estimates by ERR and CR were hardly compa-
rable, as they assess two different outcome measures (intensity versus presence of infection). At
the onset of schistosomiasis control, the primary goal is to reduce morbidity, which is reflected
by infection intensity, and hence, the ERR rather than CR might be the efficacy measure of
choice. This choice is further justified by the relatively low sensitivity of widely used diagnostic
methods, particularly the Kato-Katz technique for intestinal schistosomiasis [22,24,42] and the
Fig 6. Comparison of egg reduction rate (ERR) calculated from a single versus quadruplicate Kato-Katz thick smears, both with estimated 95%
confidence intervals (CIs). A. L’Abbé plot. For each point, the 95% CIs are shown. The red dashed diagonal line of no difference between the ERR
calculated with both metrics. The blue dashed line represents the threshold for acceptable efficacy defined by the WHO [3]. B. Bland-Altman plot. The red
dashed lines show the interval that determines the agreement of the two metrics, set at 5%. The blue dashed line represents the threshold for acceptable
efficacy defined by theWHO [3].
doi:10.1371/journal.pntd.0003821.g006
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fact that current anthelmintic drugs only show low to moderate efficacies in terms of CR
[13,46,47].
However, the situation is complex, and neither ERR nor CR alone provide a satisfactory
description of the situation. The key questions about outcome measures are between effects on
presence versus intensity of infection; and between measures of central tendency (for a group
of individuals) versus individual subject responses. Our analyses indicate that the distribution
of individual responses in egg excretion may be a better way of expressing results, as it com-
prises in one single measure drug effects on both presence and intensity of infection, and allows
further detailing the distribution in centiles–which helps identifying and quantitating the pres-
ence of poor responders. ERRAM and iERR are correlated, but the latter appears to be more apt
to detect the presence and to quantitate the magnitude of suboptimal responses to praziquan-
tel. More than 10% of individuals had ERR<90% in five studies, only two of which were identi-
fied by applying the ERRAM 90% threshold. In these two studies, with ERRAM ~82%,<30% of
individuals did not achieve a 90% reduction in their egg counts, and 11–17% had no reduction
at all.
These observations raise important questions as to which approach is best suited to assess
drug efficacy for which purpose: while ERR is, currently, the preferred measure at the program
Table 3. Data outcomes at baseline in individual positives on single or quadruplicate Kato-Katz thick smears.
Study Species Dose
(mg/kg)
% subjects
with
ERR = 0%
% subjects
with iERR
<90%
iERR 5th
centile
iERR
10th
centile
iRR 25th
centile
ERRAM
(1) Lower
limit 95%
CI(2)
Upper
limit 95%
CI(2)
Côte d'Ivoire,
2001
S.
haematobium
40 0.0% 0.0% 0.0% 98.8% 98.8% 99.4% 99.0% 100.0%
Niger, 2009 S.
haematobium
40 3.2% 13.7% 42.5% 84.6% 96.4% 95.7% 92.2% 98.1%
Côte d'Ivoire,
2010
S.
haematobium
40 1.1% 4.6% 82.4% 95.0% 99.5% 97.8% 95.9% 99.3%
Philippines,
2007
S. japonicum 40 0.0% 2.0% 97.4% 98.8% 98.8% 99.6% 99.2% 99.9%
Philippines,
2007
S. japonicum 60 0.0% 0.0% 96.8% 96.8% 96.8% 100.0% 99.9% 100.0%
Uganda, 2012 S. mansoni 40 10.8% 30.2% 0.0% 0.0% 81.1% 82.2% 72.7% 89.0%
Niger, 2007 S. mansoni 40 7.1% 36.6% 0.0% 18.2% 63.2% 81.5% 75.9% 86.8%
Brazil, 2007 S. mansoni 40 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 100.0% 100.0%
Brazil, 2007 S. mansoni 60 0.0% 0.0% 97.4% 97.4% 97.4% 100.0% 100.0% 100.0%
Mauritania,
2007
S. mansoni 40 0.0% 1.1% 96.0% 97.2% 97.2% 98.8% 96.8% 99.9%
Mauritania,
2007
S. mansoni 60 0.0% 3.2% 97.2% 99.4% 99.4% 94.0% 85.1% 99.9%
Tanzania,
2007
S. mansoni 40 1.7% 6.7% 73.2% 97.8% 99.7% 95.9% 91.7% 99.0%
Tanzania,
2007
S. mansoni 60 0.0% 2.4% 92.5% 98.1% 99.8% 98.7% 97.0% 99.7%
Côte d'Ivoire,
1997*
S. mansoni 40 3.5% 12.9% 40.5% 81.1% 97.9% 96.1% 93.2% 98.3%
Côte d'Ivoire,
1998*
S. mansoni 60 2.4% 12.9% 43.8% 82.8% 98.3% 93.6% 88.7% 96.9%
* follow-up 28 days
1Egg reduction rate (ERR).
295% confidence interval (CI) calculated using a bootstrap resampling method.
doi:10.1371/journal.pntd.0003821.t003
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level, identifying poor responders is important in view of tracking trends in responses and sig-
naling potential problem areas and emergence of drug resistance. Importantly, discussions
should be held with a variety of stakeholders, including drug regulatory authorities, especially
if new drug applications are forthcoming.
Lastly, we compared drug efficacy estimates (ERR calculated using AM and GM, and CR)
obtained by a single versus quadruplicate Kato-Katz thick smears for S.mansoni. Obviously, a
Fig 7. Comparison of cure rate (CR) calculated from a single versus quadruplicate Kato-Katz thick smears, both with estimated 95% confidence
intervals (CI). A. L’Abbé plot. For each point, the 95% CIs are shown. The red dashed diagonal line of no difference between the ERR calculated with both
metrics. B. Bland-Altman plot. The red dashed lines show the interval that determines the agreement of the two metrics, set at 5%.
doi:10.1371/journal.pntd.0003821.g007
Table 4. Drug efficacy outcomes at baseline in individuals detected positive for S.mansoni by a single or quadruplicate Kato-Katz thick smear
examinations at baseline.
Sample screened Kato-Katz
examination
n 1AMD0 2GMD0 3ERR AM
(± 95% 4CI)
ERR GM
(± 95% 4CI)
5CR
(± 95% CI)
Overall sample positive on 4 6KK
examinations
4 KK 1,435 878.7 223.7 86.9 (83.6–90.0) 99.4 (99.3–99.5) 79.6 (77.4–
81.7)
Subgroup positive on 4 and 1 KK
examinations
4 KK 1,167 1046.3 342.1 86.9 (83.3–90.6) 99.6 (99.4–99.6) 79.0 (76.7–
81.3)
1 KK 1,167 2617.5 574.8 94.92 (93.18–
96.39)
99.83 (99.78–
99.86)
88.1 (86.2–
89.9)
1Arithmetic mean (AM) at baseline
2Geometric mean (GM) at baseline
3Egg reduction rate (ERR)
495% confidence interval (CI) calculated using a bootstrap resampling method
5Cure rate (CR).
6Kato-Katz.
doi:10.1371/journal.pntd.0003821.t004
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single Kato-Katz thick smear has a lower sensitivity than multiple Kato-Katz thick smears
(here ~81%) [48], and the effect and ramifications thereof for estimating drug efficacy against
Schistosoma and other helminth infections have been discussed [42,49–51]. At the same time,
collecting single stool samples and examining single Kato-Katz thick smears is operationally
more feasible and less expensive than multiple sampling and multiple thick smear examina-
tions under a microscope. We found that, when single Kato-Katz thick smears are used, the ini-
tial intensities of infection are ~2.5 times higher than with quadruplicate thick smears; efficacy
estimation by ERRs based on AM and CR are ~8–9% higher, respectively, whereas ERRs based
on GM are similar. Taken together, these results reflect the lower sensitivity of a single Kato-
Katz thick smear, which misses low-intensity infections both on enrolment and post-treatment;
the bias appears to be proportionally greater for the initial infection intensity than for the treat-
ment outcomes. Overestimation of treatment effects may be an issue with efficacies nearing the
90% ERR threshold. In order to ascertain whether this introduces a selection bias which could
affect the estimation of efficacy [52] (i.e., if the sample positive on a single Kato-Katz thick
smear is different from that positive on multiple Kato-Katz thick smears), we compared both
baseline FECs and efficacy estimates in these two samples using the same diagnostic technique;
we found that excluding the ~19% of subjects who were negative on a single Kato-Katz selects
for subjects with marginally higher initial FECs, but has ultimately no effect on efficacy esti-
mates. Currently there is no diagnostic ‘gold’ standard method to assess Schistosoma response
to treatment [53]. Standards may need to be tailored to the study, whether a field survey (lim-
ited by practical imperatives) or a clinical trial (which could afford more complex conditions
and costly diagnosis), and whether in high or low infection intensity setting. Part of the prob-
lem, however, is the limited sensitivity of the current diagnostic methods, particularly for the
detection of low intensity infections, which cannot be corrected until and unless more reliable
tests become available [6,42,54].
Conclusions
Using group means is practical when assessing sample effects, but may not be suited to detect
small changes, especially those that may occur in early phases of decreasing drug efficacy. We
estimate that the distribution of individual responses in Schistosoma egg excretion, which
accounts for individual variability of responses to praziquantel treatment, allows measuring
effects on both presence and intensity of infection, and helps identifying and quantitating poor
responders. More research and larger databases will be required in order to identify meaningful
thresholds–e.g., centile by which 90% ERR is achieved; ERR achieved by the lowest 5% or 10%
centile–and also analyze in greater detail reasons for poor response.
Both approaches could be used in parallel and complement each-other. It is important to
agree on standardized outcome measures that are tailored to specific purposes, such as epide-
miological surveys, routine monitoring, clinical trials, morbidity control, or elimination set-
tings. Hence, we invite other groups to contribute to this discussion and scientific inquiry.
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